Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
raloxifene hydrochloride, Quantity: 60 mg
MedTAS Pty Ltd
Raloxifene hydrochloride
Tablet, film coated
Excipient Ingredients: crospovidone; magnesium stearate; povidone; microcrystalline cellulose; polysorbate 80; colloidal anhydrous silica; glycine; titanium dioxide; hypromellose; Carnauba Wax; macrogol 400
Oral
28 tablets
(S4) Prescription Only Medicine
Raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.,Raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis.Raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.
Visual Identification: White to off-white, oval, biconvex, film coated tablets with 'C' on one side and '12' on other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius
Licence status A
2014-01-14